MARKET

SELB

SELB

Selecta
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.120
-0.020
-0.93%
After Hours: 2.000 -0.12 -5.66% 19:39 03/27 EDT
OPEN
2.140
PREV CLOSE
2.140
HIGH
2.200
LOW
1.980
VOLUME
863.97K
TURNOVER
--
52 WEEK HIGH
4.830
52 WEEK LOW
1.280
MARKET CAP
183.21M
P/E (TTM)
-1.7347
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SELB and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SELB stock price target is 8.17 with a high estimate of 13.00 and a low estimate of 4.000.

EPS

SELB News

More
  • Edited Transcript of SELB earnings conference call or presentation 12-Mar-20 12:30pm GMT
  • Thomson Reuters StreetEvents · 2d ago
  • RDS.A, NRZ among premarket gainers
  • Seeking Alpha - Article · 03/19 13:20
  • Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/12 17:42
  • Selecta Biosciences EPS misses by $0.07
  • seekingalpha · 03/12 17:08

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About SELB

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.
More

Webull offers kinds of Selecta Biosciences Inc stock information, including NASDAQ:SELB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SELB stock news, and many more online research tools to help you make informed decisions.